China NMPA Drug Inspection - Gansu Fuzheng Pharmaceutical Technology Co., Ltd. - Processed Polygonum multiflorum
China NMPA drug inspection for Gansu Fuzheng Pharmaceutical Technology Co., Ltd. published December 17, 2018. Drug: Processed Polygonum multiflorum. This document, the Jiangsu Province 2018 Issue 4 Drug Quality Bulletin, released on December 17, 2018, details findings
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Gansu Fuzheng Pharmaceutical Technology Co., Ltd. published December 17, 2018. Drug: Processed Polygonum multiflorum. This document, the Jiangsu Province 2018 Issue 4 Drug Quality Bulletin, released on December 17, 2018, details findings
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox